Nanobiotix SA
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Laurent Lévy
- Full Time Employees
- 97
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 60 rue de Wattignies Paris IF France 75012
- IPO Date
- Oct 29, 2012
- Website
- nanobiotix.com
- Similar Companies
- Business
- Nanobiotix S.A. is an advanced clinical-stage biotechnology company pioneering physics-based nanotherapeutics to revolutionize cancer treatment outcomes. Its primary therapeutic candidate, NBTXR3, is a sterile suspension of hafnium oxide nanoparticles engineered to amplify the efficacy of radiation therapy directly within various solid tumors, including head and neck, soft tissue sarcoma, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancers. The company holds a global strategic partnership with Janssen Pharmaceutica for the development and commercialization of NBTXR3, complementing an existing alliance with LianBio for particular markets in Asia. Established in 2003, Nanobiotix is headquartered in Paris, France, and is listed on both Euronext Paris and Nasdaq.
Company News
Voting Rights and Shares Capital of the Company
Nanobiotix (NASDAQ:NBTX) Shares Gap Down – Time to Sell?
Nanobiotix (NASDAQ:NBTX) Sees Large Volume Increase – Still a Buy?
NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer
NANOBIOTIX Provides First Half 2026 Operational and Financial Update
Voting Rights and Shares Capital of the Company
Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Receives Average Recommendation of “Moderate Buy” from Analysts
NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer
NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Voting Rights and Shares Capital of the Company
Voting Rights and Shares Capital of the Company
Nanobiotix: A Highly Speculative Bet On A Potential Radiotherapy Platform
Nanobiotix: A Royalty-Backed Physics Platform Hidden Inside A Biotech
Voting Rights and Shares Capital of the Company
Nanobiotix Provides First Quarter 2026 Operational and Financial Update
Nanobiotix Joins the Euronext Tech Leaders Index
NANOBIOTIX Announces Closing of Global Offering
NANOBIOTIX Announces Full Exercise of Underwriters' Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris